Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Your biology might be shaping your brain disease risk more than we thought. New research presented at Neuroscience 2026 shows that biological sex, genetics, and menopause significantly influence Alzheimer's risk and chronic pain conditions like fibromyalgia. The findings point toward more personalized, precision-based treatments for some of the brain's most stubborn disorders.
Your biology might be shaping your brain disease risk more than we thought. Four new studies presented at Neuroscience 2026 — the world's largest brain science conference — reveal that biological sex, genetics, and hormonal transitions like menopause can dramatically alter how neurological disorders develop and respond to treatment. The research zeroes in on two conditions: Alzheimer's disease, which affects 35–40 million people worldwide, and fibromyalgia, a chronic pain disorder impacting 2–4% of the global population.
On the Alzheimer's front, one study found that people with genetic risk factors responded differently to menopause hormone therapy (MHT) depending on the specific hormone combination used. Another study in rodents showed that memory-related brain circuits became especially vulnerable during menopause in genetically predisposed individuals — suggesting menopause may be a critical window of heightened risk. Meanwhile, female mice in a fibromyalgia model showed stronger pain sensitivity and immune activation than males, and a separate study found that chronic gut inflammation affected Alzheimer's-related brain changes differently by sex.
Key Takeaways:
Why it matters: These findings challenge the one-size-fits-all approach to treating brain disorders. By factoring in sex and genetics, clinicians may one day offer far more targeted therapies for Alzheimer's and chronic pain — conditions that have long resisted effective treatment.